AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27544361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100mg)
Number of subjects: 406
Study 27544361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline perfusion
Number of subjects: 406
Study 27544361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100mg) and IV saline
Number of subjects: 406
Study 27544361 — intervention group
Group type: COMPARATOR
Intervention: Rectal glycerin (control)
Number of subjects: 406
Study 25161823 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (BFT) task, performed every day for about 5 min once a day.
Number of subjects: 0
Study 25161823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 0
Study 25161823 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (BFT) task.
Number of subjects: 0
Study 22089961 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene ankle-foot orthoses
Number of subjects: 8
Study 22089961 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone ankle-foot orthoses
Number of subjects: 8
Study 22089961 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 8
Study 19293589 — intervention group
Group type: EXPERIMENTAL
Intervention: LEC2 (loop electrosurgical conization in two blocks)
Number of subjects: 0
Study 19293589 — intervention group
Group type: EXPERIMENTAL
Intervention: LEC2
Number of subjects: 0
Study 19223675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (3x500 mg tablets per day for 12 days)
Number of subjects: 12
Study 19223675 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 12
Study 15649728 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU dalteparin injections once daily for 3 months
Number of subjects: 284
Study 15649728 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections once daily for 3 months
Number of subjects: 284
Study 12392217 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Aid Society-Carrera program
Number of subjects: 600
Study 12392217 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual youth program)
Number of subjects: 600
Study 10436143 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban infusion therapy (continuous intravenous infusion for 60 minutes, repeated daily for 2 weeks)
Number of subjects: 10
Study 10436143 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban infusion therapy
Number of subjects: 10
Study 7776528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg.kg‐1 + bupivacaine 5 ml
Number of subjects: 24
Study 7776528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg.kg‐1 + bupivacaine 5 ml
Number of subjects: 24
Study 7776528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg.kg‐1 + bupivacaine 5 ml
Number of subjects: 24
Study 7776528 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 5 ml only
Number of subjects: 24
Study 2109992 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 2109992 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 2109992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA)
Number of subjects: 0
Study 2109992 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (CZP)
Number of subjects: 0
Study 2109992 — intervention group
Group type: COMPARATOR
Intervention: Multiple-drug therapy
Number of subjects: 0
Study 508509 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate immediately before breakfast (EB)
Number of subjects: 16
Study 508509 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate immediately after breakfast (EA)
Number of subjects: 16
Study 508509 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base immediately before breakfast (eB)
Number of subjects: 16
Study 508509 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base immediately after breakfast (eA)
Number of subjects: 16
Study 31524779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance circuit training in hypoxia (HG)
Number of subjects: 28
Study 31524779 — intervention group
Group type: COMPARATOR
Intervention: High-resistance circuit training in normoxia (NG)
Number of subjects: 28
Study 31489467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried beancurd (100 g/day)
Number of subjects: 300
Study 31489467 — intervention group
Group type: COMPARATOR
Intervention: Rice cake (control group, 100 g/day)
Number of subjects: 300
Study 30417894 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of pressed ceramic
Number of subjects: 48
Study 30417894 — intervention group
Group type: COMPARATOR
Intervention: Two injections of pressed ceramic
Number of subjects: 48
Study 30417894 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of pressed ceramic
Number of subjects: 48
Study 30417894 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of pressed ceramic (aged)
Number of subjects: 48
Study 30417894 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of pressed ceramic (aged)
Number of subjects: 48
Study 30417894 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of pressed ceramic (aged)
Number of subjects: 48
Study 26770983 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (150 mg/day)
Number of subjects: 135
Study 26770983 — intervention group
Group type: COMPARATOR
Intervention: Control (no acarbose)
Number of subjects: 135
Study 24594561 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone self-management support/health coaching intervention for 27 weeks
Number of subjects: 0
Study 24594561 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 22314263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DMQ) 45/30 mg
Number of subjects: 379
Study 22314263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DMQ) 30/30 mg
Number of subjects: 379
Study 22314263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 20870984 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification (HH)
Number of subjects: 2833
Study 20870984 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 2833
Study 17585081 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia at 33 degrees C for 24 hours
Number of subjects: 70
Study 17585081 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 70
Study 17585081 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 70
Study 16100176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 84
Study 16100176 — intervention group
Group type: COMPARATOR
Intervention: Standard care management (control)
Number of subjects: 84
Study 12071936 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG/ALG
Number of subjects: 10
Study 10522855 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative approach with close monitoring and selective intervention (TAE or surgical intervention)
Number of subjects: 112
Study 10522855 — intervention group
Group type: COMPARATOR
Intervention: Aggressive approach with surgical intervention or attempted transarterial embolization (TAE)
Number of subjects: 112
Study 10522855 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Number of subjects: 112
Study 10522855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 112
Study 10522855 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding 36 patients with end-stage malignant neoplasms
Number of subjects: 112
Study 7742436 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Oka/Merck varicella vaccine
Number of subjects: 0
Study 7742436 — intervention group
Group type: COMPARATOR
Intervention: One dose of Oka/Merck varicella vaccine
Number of subjects: 0
Study 2139442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (324 mg/day)
Number of subjects: 105
Study 2139442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 2139442 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative beta-thromboglobulin levels
Number of subjects: 105
Study 2139442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 105
Study 7302777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 0
Study 7302777 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 0
Study 29514801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glucocorticoid injection (40 mg triamcinolone acetate)
Number of subjects: 107
Study 29514801 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 107
Study 26509817 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV methylprednisolone (neonate trial)
Number of subjects: 85
Study 26509817 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV methylprednisolone after anesthesia induction (ventricular septal defect trial)
Number of subjects: 85
Study 26509817 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg methylprednisolone in the cardiopulmonary bypass prime solution (ventricular septal defect trial)
Number of subjects: 85
Study 26509817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (neonate trial)
Number of subjects: 85
Study 26509817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ventricular septal defect trial)
Number of subjects: 85
Study 26509817 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV methylprednisolone (ventricular septal defect trial)
Number of subjects: 85
Study 24447620 — intervention group
Group type: EXPERIMENTAL
Intervention: Olesoxime (330 mg daily)
Number of subjects: 512
Study 24447620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 22421303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 162
Study 22421303 — intervention group
Group type: COMPARATOR
Intervention: Cutting balloon angioplasty
Number of subjects: 162
Study 22421303 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 162
Study 19965659 — intervention group
Group type: EXPERIMENTAL
Intervention: MEL200 (200 mg/m²)
Number of subjects: 298
Study 19965659 — intervention group
Group type: COMPARATOR
Intervention: MEL100 (100 mg/m²)
Number of subjects: 298
Study 18206857 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg/day prolonged-release methylphenidate
Number of subjects: 401
Study 18206857 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg/day prolonged-release methylphenidate
Number of subjects: 401
Study 18206857 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 mg/day prolonged-release methylphenidate
Number of subjects: 401
Study 18206857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 16816797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 0
Study 16816797 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic (perphenazine)
Number of subjects: 0
Study 12640371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LC)
Number of subjects: 30
Study 12640371 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 30
Study 10845350 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation group (videotape shown the evening before surgery)
Number of subjects: 100
Study 10845350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 8805113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% peppermint oil in ethanol solution
Number of subjects: 41
Study 8805113 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetaminophen
Number of subjects: 41
Study 8805113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (90% ethanol solution with traces of peppermint oil)
Number of subjects: 41
Study 1610539 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (24 g daily)
Number of subjects: 120
Study 1610539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (80 mg daily)
Number of subjects: 120
Study 6428899 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of hydroxy‐ethyl‐starch cryopreserved blood with free haemoglobin
Number of subjects: 5
Study 31871348 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewatching recorded lecture
Number of subjects: 102
Study 31871348 — intervention group
Group type: COMPARATOR
Intervention: Retrieval practice
Number of subjects: 102
Study 31016010 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS social skills intervention program
Number of subjects: 6
Study 24726684 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to participants with MTSS
Number of subjects: 40
Study 24726684 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to healthy participants
Number of subjects: 40
Study 24113902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) program
Number of subjects: 193
Study 24113902 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 193
Study 22325125 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher retaliatory attitudes at baseline
Number of subjects: 129
Study 22325125 — intervention group
Group type: COMPARATOR
Intervention: Retaliatory attitudes assessment
Number of subjects: 129
Study 20447535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4513
Study 20447535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4513
Study 20447535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level increases in cTnI (0.04 microg/l to <0.1 microg/l)
Number of subjects: 4513
Study 18067658 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening exercises (6 exercises for hip abductor and adductor muscles, 5 times per week for 12 weeks)
Number of subjects: 88
Study 18067658 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 88
Study 16225575 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment
Number of subjects: 183
Study 16225575 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 183
Study 12405574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (group A)
Number of subjects: 57
Study 12405574 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (group B)
Number of subjects: 57
Study 10208245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h muscle strength training session of the upper extremities
Number of subjects: 30
Study 10208245 — intervention group
Group type: COMPARATOR
Intervention: Motor performance tests (no intervention)
Number of subjects: 30
Study 8526759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic heart failure stage II
Number of subjects: 0
Study 8526759 — intervention group
Group type: COMPARATOR
Intervention: Patients without heart failure
Number of subjects: 0
Study 2223429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 8
Study 2223429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 798190 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than usual dosages of haloperidol
Number of subjects: 38
Study 798190 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 38
Study 31977882 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised early exercise program in combination with standard treatment
Number of subjects: 118
Study 31977882 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 118
Study 26179181 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (250 or 500 mg)
Number of subjects: 75
Study 26179181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29077149 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-3-n-Butylphthalide (NBP)
Number of subjects: 160
Study 29077149 — intervention group
Group type: COMPARATOR
Intervention: Routine drug therapy (Control)
Number of subjects: 160
Study 25376719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hexose correlated compound (1.0 g/d for 4 weeks)
Number of subjects: 34
Study 25376719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23778476 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin/1% prednisolone acetate fixed combination eye drops
Number of subjects: 108
Study 23778476 — intervention group
Group type: COMPARATOR
Intervention: 0.3% gatifloxacin and 1% prednisolone acetate eye drops separately (control)
Number of subjects: 108
Study 16717081 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029
Study 16717081 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 3029
Study 16717081 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemic patients
Number of subjects: 3029
Study 16717081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without anaemia at baseline
Number of subjects: 3029
Study 16717081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Hb decrease of >3 g/dL
Number of subjects: 3029
Study 16717081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Hb decrease of 2.0-3.0 g/dL
Number of subjects: 3029
Study 15259286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous combined E2 1 mg and NETA 0.25 mg
Number of subjects: 120
Study 15259286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous combined E2 1 mg and NETA 0.5 mg
Number of subjects: 120
Study 15259286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10910801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 22
Study 10910801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cell and bone marrow transplants
Number of subjects: 0
Study 8932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood, bone marrow and cord blood cell transplants
Number of subjects: 0
Study 8932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft‐versus‐host disease
Number of subjects: 0
Study 1558269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 1558269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0
Study 3901389 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD14 (2.5 mg daily for 12 weeks)
Number of subjects: 27
Study 3901389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31675674 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 117
Study 31675674 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with nutritional supplement (RTS)
Number of subjects: 117
Study 31675674 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 117
Study 30831295 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 82
Study 30831295 — intervention group
Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 82
Study 27769543 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of potassium iodide (SSKI)
Number of subjects: 0
Study 27769543 — intervention group
Group type: COMPARATOR
Intervention: No potassium iodide (control group)
Number of subjects: 0
Study 25600515 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Interpersonal Psychotherapy (IPT)
Number of subjects: 39
Study 25600515 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT)
Number of subjects: 39
Study 22079383 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFETY Intervention (SI) - home-based assessment, extensive clinical profiling, optimal pharmacology tailored to clinical stability and risk profile
Number of subjects: 320
Study 22079383 — intervention group
Group type: COMPARATOR
Intervention: Usual post-discharge care
Number of subjects: 320
Study 22079383 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFETY Intervention (SI)
Number of subjects: 320
Study 22036605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hypocretin-1 (orexin A) (435 nmol)
Number of subjects: 8
Study 19644228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-titration group (4 mg/24 h starting dose, increasing by 4 mg/24 h per week to a maximum of 24 mg/24 h)
Number of subjects: 34
Study 19644228 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-titration group (4 mg/24 h starting dose, increasing by 2 mg/24 h per week to a maximum of 24 mg/24 h)
Number of subjects: 34
Study 19644228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined results)
Number of subjects: 34
Study 17378819 — intervention group
Group type: EXPERIMENTAL
Intervention: Issuing early results from a rapid molecular test for chromosomal abnormalities
Number of subjects: 226
Study 17378819 — intervention group
Group type: COMPARATOR
Intervention: Issuing karyotype results on a fixed date
Number of subjects: 226
Study 17378819 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving rapid test results
Number of subjects: 226
Study 17378819 — intervention group
Group type: COMPARATOR
Intervention: Receiving only full karyotype results
Number of subjects: 226
Study 15650420 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 112
Study 11465621 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.0 MAC
Number of subjects: 64
Study 11465621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.8 MAC
Number of subjects: 64
Study 11465621 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.8 MAC
Number of subjects: 64
Study 11465621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 64